Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis

详细信息    查看全文

• 作者：Nadine Hainz ; Sandra Wolf ; Thomas Tschernig ; Carola Meier
• 关键词：neuroinflammation ; pannexin ; probenecid ; multiple sclerosis
• 刊名：Inflammation
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：39
• 期：1
• 页码：123-128
• 全文大小：1,243 KB
• 参考文献：1.Batoulis, H., M.S. Recks, K. Addicks, and S. Kuerten. 2011. Experimental autoimmune encephalomyelitis—achievements and prospective advances. APMIS: Acta Pathologica, Microbiologica, Et Immunologica Scandinavica 119: 819–830.CrossRef PubMed
  2.Bhaskaracharya, A., P. Dao-Ung, I. Jalilian, M. Spildrejorde, K.K. Skarratt, S.J. Fuller, R. Sluyter, and L. Stokes. 2014. Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. PLoS One 9, e93058.PubMedCentral CrossRef PubMed
  3.Bond, S.R., and C.C. Naus. 2014. The pannexins: past and present. Frontiers in physiology 5: 58.
  4.Bruzzone, R., M.T. Barbe, N.J. Jakob, and H. Monyer. 2005. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. Journal of Neurochemistry 92: 1033–1043.CrossRef PubMed
  5.Duffy, S.S., J.G. Lees, and G. Moalem-Taylor. 2014. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Multiple Sclerosis International 2014: 285245.PubMedCentral CrossRef PubMed
  6.Endong, L., J. Shijie, Y. Sonobe, M. Di, L. Hua, J. Kawanokuchi, et al. 2011. The gap-junction inhibitor carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells. Journal of neuroimmunology 240–241: 58–64.
  7.Fiebich, B.L., S. Akter, and R.S. Akundi. 2014. The two-hit hypothesis for neuroinflammation: Role of exogenous ATP in modulating inflammation in the brain. Frontiers in Cellular Neuroscience 8: 260.PubMedCentral CrossRef PubMed
  8.Graeber, M.B., W. Li, and M.L. Rodriguez. 2011. Role of microglia in CNS inflammation. FEBS Letters 585: 3798–3805.CrossRef PubMed
  9.Iglesias, R., S. Locovei, A. Roque, A.P. Alberto, G. Dahl, D.C. Spray, and E. Scemes. 2008. P2X7 receptor-Pannexin1 complex: Pharmacology and signaling. American Journal of Physiology-Cell Physiology 295: C752–C760.PubMedCentral CrossRef PubMed
  10.Locovei, S., L. Bao, and G. Dahl. 2006. Pannexin 1 in erythrocytes: Function without a gap. Proceedings of the National Academy of Sciences of the United States of America 103: 7655–7659.PubMedCentral CrossRef PubMed
  11.Locovei, S., J. Wang, and G. Dahl. 2006. Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. FEBS Letters 580: 239–244.CrossRef PubMed
  12.Locovei, S., E. Scemes, F. Qiu, D.C. Spray, and G. Dahl. 2007. Pannexin1 is part of the pore forming unit of the P2X(7) receptor death complex. FEBS Letters 581: 483–488.PubMedCentral CrossRef PubMed
  13.Lutz, S.E., E. Gonzalez-Fernandez, J.C. Ventura, A. Perez-Samartin, L. Tarassishin, H. Negoro, N.K. Patel, S.O. Suadicani, S.C. Lee, C. Matute, and E. Scemes. 2013. Contribution of pannexin1 to experimental autoimmune encephalomyelitis. PLoS One 8, e66657.PubMedCentral CrossRef PubMed
  14.Matute, C., I. Torre, F. Perez-Cerda, A. Perez-Samartin, E. Alberdi, E. Etxebarria, A.M. Arranz, R. Ravid, A. Rodriguez-Antiguedad, M. Sanchez-Gomez, and M. Domercq. 2007. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. The Journal of Neuroscience 27: 9525–9533.CrossRef PubMed
  15.Meier, C., J. Middelanis, B. Wasielewski, S. Neuhoff, A. Roth-Haerer, M. Gantert, et al. 2006. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatric research 59(2): 244–9.
  16.Negoro, H., S.E. Lutz, L.S. Liou, A. Kanematsu, O. Ogawa, E. Scemes, and S.O. Suadicani. 2013. Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model. Science Reports 3: 2152.
  17.Pelegrin, P., and A. Surprenant. 2006. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. The EMBO Journal 25: 5071–5082.PubMedCentral CrossRef PubMed
  18.Robbins, N., S.E. Koch, M. Tranter, and J. Rubinstein. 2012. The history and future of probenecid. Cardiovascular Toxicology 12: 1–9.CrossRef PubMed
  19.Sharp, A.J., P.E. Polak, V. Simonini, S.X. Lin, J.C. Richardson, E.R. Bongarzone, and D.L. Feinstein. 2008. P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. Journal of Neuroinflammation 5: 33.PubMedCentral CrossRef PubMed
  20.Silverman, W., S. Locovei, and G. Dahl. 2008. Probenecid, a gout remedy, inhibits pannexin 1 channels. American Journal of Physiology-Cell Physiology 295: C761–C767.PubMedCentral CrossRef PubMed
  21.Silverman, W.R., J.P. de Rivero Vaccari, S. Locovei, F. Qiu, S.K. Carlsson, E. Scemes, R.W. Keane, and G. Dahl. 2009. The pannexin 1 channel activates the inflammasome in neurons and astrocytes. The Journal of Biological Chemistry 284: 18143–18151.PubMedCentral CrossRef PubMed
  22.Talbott, J.H. 1953. Diagnosis and treatment of gouty arthritis. California Medicine 79: 220–226.PubMedCentral PubMed
  23.Williams, S.K., O. Maier, R. Fischer, R. Fairless, S. Hochmeister, A. Stojic, L. Pick, D. Haar, S. Musiol, M.K. Storch, K. Pfizenmaier, and R. Diem. 2014. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One 9, e90117.PubMedCentral CrossRef PubMed
  24.Woehrle, T., L. Yip, A. Elkhal, Y. Sumi, Y. Chen, Y. Yao, P.A. Insel, and W.G. Junger. 2010. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 116: 3475–3484.PubMedCentral CrossRef PubMed
  
• 作者单位：Nadine Hainz (1)
  Sandra Wolf (1)
  Thomas Tschernig (1)
  Carola Meier (1)
  
  1. Department of Anatomy and Cell Biology, Saarland University, Building 61, 66421, Homburg, Saar, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  Internal Medicine
  Pharmacology and Toxicology
  Pathology
  
• 出版者：Springer Netherlands
• ISSN：1573-2576

文摘

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Neurological impairments are caused by axonal damage due to demyelination and neuroinflammation within the central nervous system. T cells mediate the neuroinflammation. The activation of T cells is induced by the release of adenosine triphosphate and involves purinergic receptors as well as pannexin (Panx) proteins. As Panx1 is expressed on T cells, we here propose that application of probenecid, a known Panx inhibitor, will prevent the onset of clinical symptoms in a mouse model of MS, the experimental autoimmune encephalomyelitis (EAE) model. EAE-induced mice received daily injections of probenecid. Disease scores, T cell numbers, and microglia activation were compared between experimental groups. Probenecid treatment resulted in lower disease scores as compared to EAE animals. Probenecid-treated animals also displayed fewer inflammatory lesions. Microglia activation was not altered by treatment. In conclusion, probenecid prevented the onset of EAE. KEY WORDS neuroinflammation pannexin probenecid multiple sclerosis